Geckopico: Add a longevity or biotech research image to the Calico page

2026-06-08T08:17:12Z

Add a longevity or biotech research image to the Calico page

← Older revision		Revision as of 08:17, 8 June 2026
Line 5:		Line 5:
	== Overview ==		== Overview ==


			[[File:Googleplex HQ (cropped).jpg\|thumb\|right\|Alphabet Inc. logo — Calico operates as a subsidiary of Alphabet, Google's parent holding company.]]
	Calico was announced in September 2013, with Arthur Levinson — former CEO of Genentech and chairman of Apple's board — appointed as CEO and co-founder. The company operates as a subsidiary of [[Alphabet]], Google's parent holding company, and is headquartered in South San Francisco, California.		Calico was announced in September 2013, with Arthur Levinson — former CEO of Genentech and chairman of Apple's board — appointed as CEO and co-founder. The company operates as a subsidiary of [[Alphabet]], Google's parent holding company, and is headquartered in South San Francisco, California.

Geckopico: Add longevity/life extension image to Calico page

2026-06-08T08:07:40Z

Add longevity/life extension image to Calico page

← Older revision		Revision as of 08:07, 8 June 2026
Line 1:		Line 1:
	'''Calico''' (California Life Company) is a research and development company established by [[Google]] (now [[Alphabet]]) in September 2013, focused on understanding the biology of ageing and developing interventions to extend the healthy human lifespan. Founded under the direction of Google co-founder Larry Page and biotechnology veteran Arthur Levinson, Calico represents one of the most well-funded and secretive efforts by the Silicon Valley elite to tackle human mortality as an engineering problem. Some researchers and commentators situate Calico within the broader [[Transhumanist Agenda]] — the drive by a small, extraordinarily wealthy class to transcend biological limitations and, potentially, achieve indefinite lifespans.		'''Calico''' (California Life Company) is a research and development company established by [[Google]] (now [[Alphabet]]) in September 2013, focused on understanding the biology of ageing and developing interventions to extend the healthy human lifespan. Founded under the direction of Google co-founder Larry Page and biotechnology veteran Arthur Levinson, Calico represents one of the most well-funded and secretive efforts by the Silicon Valley elite to tackle human mortality as an engineering problem. Some researchers and commentators situate Calico within the broader [[Transhumanist Agenda]] — the drive by a small, extraordinarily wealthy class to transcend biological limitations and, potentially, achieve indefinite lifespans.

			[[File:Manual of Style Governing Composition and Proof Reading in the Government printing Office Together With Decisions of the Board on Geographic Names 1890-1899.djvu\|thumb\|right\|Alphabet Inc., Google's parent company, established Calico in 2013 as a dedicated longevity research subsidiary.]]

	== Overview ==		== Overview ==

Geckopico: Create: Calico

2026-05-28T04:13:39Z

Create: Calico

New page

'''Calico''' (California Life Company) is a research and development company established by [[Google]] (now [[Alphabet]]) in September 2013, focused on understanding the biology of ageing and developing interventions to extend the healthy human lifespan. Founded under the direction of Google co-founder Larry Page and biotechnology veteran Arthur Levinson, Calico represents one of the most well-funded and secretive efforts by the Silicon Valley elite to tackle human mortality as an engineering problem. Some researchers and commentators situate Calico within the broader [[Transhumanist Agenda]] — the drive by a small, extraordinarily wealthy class to transcend biological limitations and, potentially, achieve indefinite lifespans.

== Overview ==

Calico was announced in September 2013, with Arthur Levinson — former CEO of Genentech and chairman of Apple's board — appointed as CEO and co-founder. The company operates as a subsidiary of [[Alphabet]], Google's parent holding company, and is headquartered in South San Francisco, California.

Its stated mission is to "harness advanced technologies to increase our understanding of the biology that controls lifespan, and to use that knowledge to devise interventions that enable people to lead longer and healthier lives." In practice, this means Calico functions as a long-horizon R&D laboratory — not a conventional pharmaceutical company — focused on foundational research into the mechanisms of biological ageing.

Calico recruited a significant roster of top-tier scientists from fields including molecular biology, genetics, computational biology, and neuroscience. Unlike a traditional biotech startup, it does not operate under short-term profit pressures, giving it unusual freedom to pursue decades-long research goals.

What distinguishes Calico from other longevity ventures is not just the scale of its funding but the identity of those backing it. Google's founders have made no secret of their belief that death itself is a problem to be solved — a position that aligns closely with the philosophical framework of [[Transhumanism]].

== Funding and Backing ==

At its founding, Google committed a reported '''$730 million''' to Calico, making it one of the best-funded longevity ventures in history at the time of its creation. This was later supplemented by the AbbVie partnership (see below), bringing the total committed funding to over '''$1.5 billion'''.

Arthur Levinson brought significant credibility and a deep network within the pharmaceutical and biotech establishment. His dual role as chairman of Apple and CEO of Calico raised questions among some observers about interlocking interests at the highest levels of the technology and pharmaceutical industries.

Google's co-founder Larry Page described ageing research as among the most impactful investments the company could make, framing mortality itself as a technical challenge. Sergey Brin has separately expressed interest in neurological longevity, given his disclosed risk factors for Parkinson's disease.

The involvement of [[Alphabet]] — which also funds [[DARPA]]-adjacent moonshot projects through its X division — places Calico within a constellation of elite-backed, long-horizon initiatives aimed at reshaping the human condition.

== Research Areas ==

Calico's research portfolio, to the extent it has been made public, covers several intersecting areas:

* '''Molecular biology of ageing''' — studying the cellular and genetic mechanisms that drive biological senescence, including telomere dynamics, mitochondrial dysfunction, and senescent cell accumulation.
* '''Genomics and longevity biomarkers''' — analysing the genomes of exceptionally long-lived individuals and species (including the naked mole rat, a focus of early Calico research) to identify genetic factors associated with extended lifespan.
* '''Drug discovery''' — identifying and developing compounds capable of modifying ageing-related pathways, including senolytics (drugs that clear senescent cells), mTOR inhibitors, and NAD+ precursors.
* '''Computational biology''' — deploying machine learning and data science tools to map ageing processes at scale, a natural fit given Calico's parent company's core competencies.
* '''Model organisms''' — Calico has published research on the naked mole rat (''Heterocephalus glaber''), a rodent notable for its negligible senescence and extraordinary longevity relative to its size.

Despite the scale of its funding and the calibre of its scientists, Calico has published relatively little peer-reviewed research, leading to significant criticism regarding the pace and transparency of its work.

== AbbVie Partnership ==

In 2014, Calico announced a major joint venture with '''AbbVie''', a multinational pharmaceutical company spun off from Abbott Laboratories. Under the agreement:

* Both companies committed up to '''$500 million each''', for a potential total of '''$1 billion''' in joint funding.
* AbbVie provided drug development expertise, regulatory experience, and commercialisation infrastructure — capabilities Calico lacked as a pure research organisation.
* The partnership focused specifically on identifying and developing new therapeutics in neurodegeneration and cancer, both of which are closely linked to the biology of ageing.

The AbbVie deal was widely interpreted as Calico's attempt to build a pipeline from fundamental research to actual medicines without building a full pharmaceutical company from scratch. Critics noted that AbbVie's commercial incentives could conflict with Calico's stated long-horizon mission.

The partnership has been extended and expanded in subsequent years, though details of specific drug candidates in development have remained largely undisclosed to the public.

== Connections to the Transhumanist Agenda ==

Calico cannot be fully understood without situating it within the broader elite project of [[Transhumanism]] — the philosophical and technological movement that seeks to transcend human biological limitations through science and technology.

[[Ray Kurzweil]], Google's Director of Engineering and one of Transhumanism's most prominent advocates, has long predicted that radical life extension will be achievable within decades. While Kurzweil does not formally work for Calico, his presence within the same corporate family reflects a coherent institutional ideology: that human biology is a legacy system to be upgraded.

Some researchers and commentators argue that elite investment in life extension is not merely philanthropic curiosity but represents a class project — the aspiration of a transnational technocratic elite to exempt themselves from mortality while ordinary populations remain subject to it. In this reading, Calico is one node in a broader network that includes [[DARPA]]'s human enhancement programs, [[World Economic Forum]] discussions of human augmentation, and related ventures.

The framing of death as a "disease" — promoted by figures at Calico and across the longevity sector — has been criticised by bioethicists and theologians alike as a category error with potentially profound social and spiritual consequences.

== Silicon Valley Life Extension Network ==

Calico exists within a dense ecosystem of elite-backed longevity research:

* '''Aubrey de Grey''' and the '''SENS Research Foundation''' (Strategies for Engineered Negligible Senescence) pursued overlapping goals through a more open, academic model. De Grey's work on repairing age-related damage at the cellular level parallels some of Calico's research interests, though the two organisations have operated largely independently. See: [[Aubrey de Grey]].

* '''Peter Thiel''', co-founder of PayPal and Palantir, has been one of Silicon Valley's most vocal investors in longevity research. Thiel has funded the SENS Foundation and has spoken publicly about his personal interest in avoiding death. He has also drawn controversy for reported interest in '''parabiosis''' — the transfusion of blood from young donors to older recipients as a longevity intervention. See: [[Peter Thiel]] and [[Parabiosis]].

* '''Unity Biotechnology''', '''Altos Labs''' (backed by Jeff Bezos and Yuri Milner), and '''BioAge''' are among a growing cohort of well-funded longevity companies, suggesting a coordinated — if not formally organised — push by the ultra-wealthy toward radical life extension.

* The '''Buck Institute for Research on Aging''' and the '''National Institute on Aging''' represent the institutional science layer supporting these efforts.

Together, these entities form what some observers describe as a '''Silicon Valley Life Extension Network''' — an informal coalition of capital, science, and ideology oriented toward defeating biological ageing.

== Transparency and Secrecy ==

Calico has attracted sustained criticism for its extreme opacity. Despite having operated for over a decade and having received over a billion dollars in funding, the company has:

* Published a relatively small number of peer-reviewed papers compared to similarly funded academic institutions.
* Declined to publicly disclose which specific drug candidates it is developing or what its current research priorities are.
* Granted few interviews and held no public-facing events describing its scientific progress.
* Operated without the disclosure requirements that publicly listed pharmaceutical companies face.

Critics — including scientists within the longevity field — have questioned whether Calico's secrecy reflects genuine scientific caution, strategic protection of intellectual property, or simply slow progress relative to the scale of its ambitions.

The opacity is particularly notable given that Calico's parent company, [[Alphabet]], is one of the world's largest collectors of human health and behavioural data. The intersection of Google's data infrastructure with Calico's biological research agenda has received almost no public scrutiny.

== Ethical Implications ==

The project of radical life extension raises fundamental ethical questions that Calico and its backers have largely declined to engage with publicly:

* '''Class-based immortality''' — if radical life extension technologies are developed but remain expensive, they will be accessible only to the ultra-wealthy. Some analysts describe this as the ultimate expression of inequality: a biological divide between those who can afford to live indefinitely and those who cannot. See: [[Eugenics]] and [[Depopulation Agenda]].

* '''Demographic consequences''' — indefinite lifespans among a small elite would have profound effects on wealth distribution, political power, and intergenerational dynamics. Population scientists note that even modest extensions of elite lifespan, without corresponding extensions across the population, would dramatically concentrate power.

* '''Resource allocation''' — significant capital directed toward life extension for the wealthy could crowd out investment in basic healthcare for the global majority.

* '''Theological and philosophical objections''' — many religious and philosophical traditions hold that mortality is constitutive of human life and meaning. The drive to eliminate death is, from this perspective, not a neutral scientific project but a profound act of hubris with spiritual dimensions.

* '''Consent and governance''' — there is no democratic mandate for or meaningful public deliberation about the societal implications of life extension technologies. The agenda is being set by a small number of extraordinarily wealthy individuals and the institutions they control.

== See Also ==

* [[Transhumanist Agenda]]
* [[Ray Kurzweil]]
* [[Peter Thiel]]
* [[Aubrey de Grey]]
* [[Parabiosis]]
* [[DARPA]]
* [[World Economic Forum]]
* [[Klaus Schwab]]
* [[Eugenics]]
* [[Depopulation Agenda]]
* [[Alphabet]]

== References ==

* Calico official website (calicolabs.com)
* Time magazine, "Can Google Solve Death?", September 2013
* AbbVie/Calico partnership announcements, 2014–2018
* Aubrey de Grey, ''Ending Aging'' (2007)
* Various peer-reviewed publications from Calico researchers on naked mole rat biology and ageing genomics

[[Category:Organisations]]
[[Category:Transhumanist Agenda]]
[[Category:Life Extension]]
[[Category:Technology]]
[[Category:Emerging Technologies]]

Calico - Revision history

Geckopico: Add a longevity or biotech research image to the Calico page

Geckopico: Add longevity/life extension image to Calico page

Geckopico: Create: Calico